The FDA approved the first over-the-counter glucose monitoring system designed to help with weight management.
Developed by health technology company Signos, the system combines the Stelo by Dexcom glucose biosensor with an AI-driven app that provides feedback based on users’ glucose levels, according to an Aug. 20 news release from the company.
The system allows individuals to monitor how their bodies are responding to food, physical activity, stress and sleep with a goal of supporting weight management.
Customers who sign up through the company can choose a three-month for $139 per month or a six-month plan for $129 per month. Insurers do not cover the system for weight management, but Signos told CNBC it is working with insurance companies to arrange coverage for the system.
The glucose system is available without a prescription, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
